Yuxuan Wu, Zou Xiang. The combination of DNA methyltransferase inhibitor therapy and immunotherapy for acute myeloid leukemia[J]. Blood&Genomics, 2021, 5(2): 97-106. DOI: 10.46701/BG.2021022021132
Citation: Yuxuan Wu, Zou Xiang. The combination of DNA methyltransferase inhibitor therapy and immunotherapy for acute myeloid leukemia[J]. Blood&Genomics, 2021, 5(2): 97-106. DOI: 10.46701/BG.2021022021132

The combination of DNA methyltransferase inhibitor therapy and immunotherapy for acute myeloid leukemia

  • Acute myeloid leukemia (AML), the most common form of acute leukemia in adults, is characterized by abnormal proliferation and blocked maturation and differentiation of myeloid precursor cells. AML is an aggressive cancer that progresses rapidly without treatment. Therefore, effective treatment modalities should be implemented immediately after diagnosis. The mainstay of classical AML therapy has been chemotherapy, which is not suitable for relapsing or refractory patients, especially elderly patients. Among emerging novel therapeutic approaches for AML, epigenetic therapy and immunotherapy represent two exciting therapeutic developments. This review focuses on discussion of the therapeutic considerations for AML from the perspective of combination treatment, which incorporates both DNA methyltransferase inhibitor therapy, as one of the most promising epigenetic therapies, and immune checkpoint inhibitor or dendritic cell-based vaccination treatments, as examples of immunotherapy. Both challenges and rationale in the optimization of therapeutic approaches, as well as recent clinical trial developments, along this line are summarized.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return